Role of phospholipase A2 on the variations of the choline signal intensity observed by 1H magnetic resonance spectroscopy in brain diseases

Brain Research Reviews

Volumn 33, Issue 2-3, 2000, Pages 380-389

  Boulanger, Yvan ^a   Labelle, Martin ^a   Khiat, Abdesslem ^a  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Brain disease; Choline; Magnetic resonance spectroscopy; Metabolism; Phospholipase A2; Phospholipids

Indexed keywords

CHOLINE; GLYCEROPHOSPHORYLCHOLINE; GLYCOPHOSPHOLIPID; MEMBRANE PHOSPHOLIPID; PHOSPHOLIPASE; PHOSPHOLIPASE A2; PHOSPHORYLCHOLINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AGING; ALZHEIMER DISEASE; BRAIN DISEASE; BRAIN TUMOR; CANAVAN DISEASE; CRYPTOCOCCOSIS; DEPRESSION; DIAGNOSTIC ACCURACY; ENZYME ACTIVITY; GRAVES DISEASE; HEAD INJURY; HEPATIC ENCEPHALOPATHY; HUMAN; HUNTINGTON CHOREA; MANIC DEPRESSIVE PSYCHOSIS; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA; TECHNIQUE; TOXOPLASMOSIS;

EID: 0033818216     PISSN: 01650173     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-0173(00)00037-0     Document Type: Review

References (114)

1. Akampong T., Spencer R.L., McEwen B.S. Glucocorticoids inhibit soluble phospholipase C activity and cytosolic guanine nucleotide regulatory protein-alpha i immunoreactivity in spleen. Endocrinology. 133:1993;1963-1970.
2. Barker P.B., Bryan R.N., Kumar A.J., Naidu S. Proton NMR spectroscopy of Canavan's disease. Neuropediatrics. 23:1992;263-267.
3. Bazan N.G., Allan G. Platelet-activating factor and other bioactive lipids. Ginsberg M.D., Bogousslavski J. Cerebrovascular Disease: Pathophysiology, Diagnosis, and Management. 1998;532-555 Blackwell Sciences, Malden MA.
4. Bertolino A., Nawroz S., Mattay V.S., Barnett A.S., Duyn J.H., Moonen C.T., Frank J.A., Tedeschi G., Weinberger D.R. Regionally specific pattern of neurochemical pathology in schizophrenia as assessed by multislice proton magnetic resonance spectroscopic imaging. Am. J. Psychiatry. 153:1996;1554-1563.
5. Bhatara V.S., Tripathi R.P., Sankar R., Gupta A., Khushu S. Frontal lobe proton magnetic-resonance spectroscopy in Graves' disease: a pilot study. Psychoneuroendocrinology. 3:1998;605-612.
6. 31P magnetic resonance spectroscopy reveals osmotic and metabolic disturbances in human hepatic encephalopathy. J. Neurochem. 71:1998;1564-1576.
7. Blusztajn J.K., Wurtman R.J. Choline and cholinergic neurons. Science. 221:1983;614-621.
8. Brenner R.E., Munro P.M.G., Williams S.C.R., Bell J.D., Barker G.J., Hawkins C.P., Landon D.N., McDonald W.I. The proton NMR spectrum in acute EAE: the significance of the change in the Cho: Cr ratio. Magn. Reson. Med. 29:1993;737-745.
9. 1H-magnetic resonance spectroscopy of the left temporal and frontal lobes in schizophrenia: clinical, neurodevelopmental, and cognitive correlates. Biol. Psychiatry. 36:1994;792-800.
10. Cabré E., Periago J.L., González J., González-Huix F., Abad-Lacruz A., Gil A., Sánchez-Medina F., Esteve-Comas M., Fernández-Bañares F., Planas R., Gassull M.A. Plasma polyunsaturated fatty acids in liver cirrhosis with or without chronic hepatic encephalopathy: a preliminary study. JPEN J. Parenter. Enteral Nutr. 16:1992;359-363.
11. Cadoux-Hudson T.A., Kermode A., Rajagopalan B., Taylor D., Thompson A.J., Ormerod I.E., McDonald W.I., Radda G.K. Biochemical changes within a multiple sclerosis plaque in vivo. J. Neurol. Neurosurg. Psychiatry. 54:1991;1004-1006.
12. Carnero A., Cuadrado A., del Peso L., Lacal J.C. Activation of type D phospholipase by serum stimulation and ras-induced transformation in NIH-3T3 cells. Oncogene. 9:1994;1387-1395.
13. Chang L., Miller B.L., McBride D., Cornford M., Oropilla G., Buchthal S., Chiang F., Aronow H., Ernst T. Brain lesions in patients with AIDS: H-1 MR spectroscopy. Radiology. 197:1995;525-553.
14. Chang L., Ernst T., Poland R.E., Jenden D.J. In vivo proton magnetic resonance spectroscopy of the normal aging human brain. Life Sci. 58:1996;2049-2056.
15. Chang L., Cornford M.E., Chiang F.L., Ernst T.M., Sun N.C.J., Miller B.L. Radiologic-pathologic correlation. Cerebral toxoplasmosis and lymphoma in AIDS. AJNR Am. J. Neuroradiol. 16:1995;1653-1663.
16. Charles H.C., Lazeyras F., Krishnan K.R., Boyko O.B., Patterson L.J., Doraiswamy P.M., McDonald W.M. Proton spectroscopy of human brain: effects of age and sex. Prog. Neuropsychopharmacol. Biol. Psychiatry. 18:1994;995-1004.
17. Charles H.C., Lazeyras F., Krishnan K.R., Boyko O.B., Payne M., Moore D. Brain choline in depression: in vivo detection of potential pharmacodynamic effects of antidepressant therapy using hydrogen localized spectroscopy. Prog. Neuropsychopharmacol. Biol. Psychiatry. 18:1994;1121-1127.
18. 1H magnetic resonance spectroscopy characterization of neuronal dysfunction in drug-naive, chronic schizophrenia. Acad. Radiol. 1:1994;211-216.
19. 2 after transient global forebrain ischemia in the rat. Stroke. 27:1996;527-535.
20. Cohen B.M., Renshaw P.F., Stoll A.L., Wurtma R.J., Yurgelun-Todd D., Babb S.M. Decreased brain choline uptake in older adults. An in vivo proton magnetic resonance spectroscopy study. J. Am. Med. Assoc. 274:1995;902-907.
21. Cruz C.J., Aminoff M.J., Meyerhoff D.J., Graham S.H., Weiner M.W. Proton MR spectroscopic imaging of the striatum in Parkinson's disease. Magn. Reson. Imaging. 15:1997;619-624.
22. Danielsen E.R., Ross B. Magnetic resonance spectroscopy diagnosis of neurological diseases. 1999;Marcel Dekker, Inc, New York.
23. Dechent P., Pouwels P.J.W., Frahm J. Neither short-term nor long-term administration of oral choline alters metabolite concentrations in human brain. Biol. Psychiatry. 46:1999;406-411.
24. Deicken R.F., Fein G., Weiner M.W. Abnormal frontal lobe phosphorous metabolism in bipolar disorder. Am. J. Psychiatry. 152:1995;915-918.
25. Deicken R.F., Johnson C., Eliaz Y., Schuff N. Reduced concentrations of thalamic N-acetylaspartate in male patients with schizophrenia. Am. J. Psychiatry. 157:2000;644-647.
26. 2. J. Biol. Chem. 269:1994;13057-13060.
27. 2 superfamily of signal transduction enzymes. Trends Biochem. Sci. 22:1997;1-2.
28. Duijn J.H., Matson G.B., Maudsley A.A., Hugg J.W., Weiner M.W. Human brain infarction: proton MR spectroscopy. Radiology. 183:1992;711-718.
29. 2 in neurodegeneration. Neurochem. Int. 30:1997;517-522.
30. 2 and signal transduction. Brain Res. Rev. 21:1995;152-161.
31. Federico F., Simone I.L., Lucivero V., Giannini P., Laddomada G., Mezzapesa D.M., Rortorella C. Prognostic value of proton magnetic resonance spectroscopy in ischemic stroke. Arch. Neurol. 55:1998;489-494.
32. Ferretti A., Podo F., Carpineli G., Chen L.L., Borghi P., Masella R. Detection of neutral phosphatidylcholine-specific phospholipase C in Friend leukemia cells before and after erythroid differentiation. Anticancer Res. 13:1993;2309-2318.
33. Fujimoto T., Nakano T., Takano T., Takeuchi K., Yamada K., Fukuzako T., Akimoto H. Proton magnetic resonance spectroscopy of basal ganglia in chronic schizophrenia. Biol. Psychiatry. 40:1996;14-18.
34. Fukuzako H., Takeuchi K., Hokazono Y., Fukuzako T., Yamada K., Hashiguchi T., Obo Y., Ueyama K., Takigawa M., Fujimoto T. Proton magnetic resonance spectroscopy of the left medial temporal and frontal lobes in chronic schizophrenia: preliminary report. Psychiatry Res. 61:1995;193-200.
35. nd edition :1995;283 Oxford University Press, Oxford.
36. Garnett M.R., Corkill R.G., Cadoux-Hudson T.A.D., Blamire A.M., Rajagopalan B., Styles P. Early proton MRS in normal appearing frontal white matter correlates with injury severity and outcome in patients following traumatic brain injury. International Society for Magnetic Resonance in Medicine, Eighth Scientific Meeting and Exhibition. Denver CO :2000.
37. Glen A.I.M., Peet M., Horrobin D.F. Phospholipid Spectrum Disorder in Psychiatry. 1999;340 Marius Press, Carnworth.
38. 2 activity from the 106,000 X g pellet (microsomal fraction) of bovine brain acting on phosphatidylinositol. Can. J. Biochem. 60:1982;108-117.
39. Hamakawa H., Kato T., Murashita J., Kato N. Quantitative proton magnetic resonance spectroscopy of the basal ganglia in patients with affective disorders. Eur. Arch. Psychiatry Clin. Neurosci. 248:1998;53-58.
40. Harder D.R., Narayanan J., Gebremedhin D., Roman R.J. Transduction of physical forces by the vascular wall: role of phospholipase C and cytochrome P450 metabolites of arachidonic acid. Trends Cardiovasc. Med. 5:1995;7-14.
41. 31P-spectroscopy of intracranial tumors in 43 patients. J. Comput. Assist. Tomogr. 12:1988;907-916.
42. 2 from bovine brain cytosol. J. Neurochem. 59:1992;708-714.
43. 1H MRS in the evaluation of Huntington's and Parkinson's diseases. Neurology. 50:1998;1033-1040.
44. 2 in postmortem white matter from patients with multiple sclerosis. Neurochem. Res. 20:1995;1335-1343.
45. 2A) in the Darier's disease (DAR) region of chromosome 12q23-q24.1. Psychiatr. Genet. 6:1996;195-199.
46. 1H NMR spectroscopy. Neurology. 43:1993;2689-2695.
47. Kato T., Takahashi S., Shioiri T., Inubushi T. Brain phosphorous metabolism in depressive disorders detected by phosphorus-31 magnetic resonance spectroscopy. J. Affect. Disord. 26:1992;223-230.
48. Katz-Brull R., Degani H. Kinetics of choline transport and phosphorylation in human breast cancer cells; NMR application of the zero trans method. Anticancer Res. 16:1996;1375-1380.
49. Ke Y., Lange N., Renshaw P.F., Babb S.M., Yang M.Q., Kaufman M., Yurgelun-Todd D.A., Stoll A.L., Cohen B.M. Increased brain choline level observed after choline bitartrate ingestion. International Society for Magnetic Resonance in Medicine, Eighth Scientific Meeting and Exhibition. Denver CO :2000.
50. Khiat A., Bard C., Lacroix A., Boulanger Y. Recovery of the brain choline level in treated Cushing's patients as monitored by proton magnetic resonance spectroscopy. Brain Res. 862:2000;301-307.
51. Khiat A., Bard C., Lacroix A., Rousseau J., Boulanger Y. Brain metabolic alterations in Cushing's syndrome as monitored by proton magnetic resonance spectroscopy. NMR Biomed. 12:1999;357-363.
52. 2 activity of senescence-accelerated mouse is increased in age-dependent manner. Neurosci. Res. 29:1997;269-272.
53. 2 but not from phospholipase D. Brain Res. 630:1993;337-340.
54. Kobayashi M., Kanfer J.N. Phosphatidylethanol formation via transphosphatidylation by rat brain phospholipase D. Neurochemistry. 48:1987;1597-1603.
55. 2 activity: evidence for glucocorticoid receptor-mediated regulation. Mol. Cell. Endocrinol. 137:1998;117-125.
56. 1H NMR spectroscopy in patients with chronic hepatic encephalopathy. Analysis of changes in cerebral glutamine, choline and inositols. NMR Biomed. 4:1991;109-116.
57. Kreis R., Ross B.D., Farrow N.A., Ackerman Z. Metabolic disorders of the brain in chronic hepatic encephalopathy detected with H-1 MR spectroscopy. Radiology. 182:1992;19-27.
58. 31P magnetic resonance spectroscopy (MRS) study in basal ganglia of patients with Parkinson's disease] (article in Japanese). Nippon Rinsho. 55:1997;255-261.
59. 1H NMR spectroscopy in vivo. NMR Biomed. 7:1994;231-236.
60. 19F in vivo NMR spectroscopy of aged rat brain. NMR Biomed. 4:1991;38-40.
61. Lien Y.-H.H., Shapiro J.L., Chan L. Effects of hypernatremia on organic brain osmoles. J. Clin. Invest. 85:1990;1427-1435.
62. Löffelholz K., Klein J., Köppen A. Choline, a precursor of acetylcholine and phospholipids in the brain. Prog. Brain Res. 98:1993;197-200.
63. Maier M., Ron M.A., Barker G.J., Tofts P.S. Proton magnetic resonance spectroscopy: an in vivo method of estimating hippocampal neuronal depletion in schizophrenia. Psychol. Med. 25:1995;1201-1209.
64. Matthews P.M., Francis G., Antel J., Arnold D.L. Proton magnetic resonance spectroscopy for metabolic characterization of plaques in multiple sclerosis. Neurology. 41:1991;1251-1256.
65. 31P NMR spectroscopy detects altered phospholipid metabolism in Alzheimer's disease. Can. J. Neurol. Sci. 13:(4 Suppl.):1986;535-539.
66. 1H NMR spectroscopy: N-acetyl-L-aspartate, creatine and choline. NMR Biomed. 4:1991;47-52.
67. 1H MRS choline: correlation with in vitro chemistry/histology. Life Sci. 58:1996;1929-1935.
68. Moats R.A., Ernst T., Shonk T.K., Ross B.D. Abnormal cerebral metabolite concentrations in patients with probable Alzheimer disease. Magn. Reson. Med. 32:1994;110-115.
69. Moscat J., Cornet M.E., Diaz-Meco M.T., Larrodera P., Lopez-Alanon D., Lopez-Barahona M. Activation of phosphatidylcholine-specific phospholipase C in cell oncogene transformation. Biochem. Soc. Trans. 17:1989;988-991.
70. rd edition Harper's Biochemistry. 1993;245-246 Prentice-Hall International Inc, Toronto.
71. Narayanan J., Imig M., Roman R.J., Harder D.R. Pressurization of isolated renal arteries increases inositol triphosphate and diacylglycerol. Am. J. Physiol. 266:1994;H1840-H1845.
72. 2 activity in schizophrenics and other psychiatric patients. Biol. Psychiatry. 34:1993;641-649.
73. Pettegrew J.W., Keshavan M.S., Panchalingam K., Strychor S., Kaplan D.B., Tretta M.G., Allen M. Alterations in brain high-energy phosphate and membrane phospholipid metabolism in first-episode, drug-naive schizophrenics. A pilot study of the dorsal prefrontal cortex by in vivo phosphorus 31 nuclear magnetic resonance spectroscopy. Arch. Gen. Psychiatry. 48:1991;563-568.
74. 1H NMR analysis at 4.7 and 14.1 Tesla. J. Magn. Reson. 67:1986;443-450.
75. 31P nuclear magnetic resonance studies of phosphoglyceride metabolism in developing and degenerating brain: preliminary observations. J. Neuropathol. Exp. Neurol. 46:1987;419-430.
76. Pfefferbaum A., Adalsteinsson E., Spielman D., Sullivan E.V., Lim K.O. In vivo spectroscopic quantification of the N-acetyl moiety, creatine, and choline from large volumes of brain gray and white matter: effects of normal aging. Magn. Reson. Med. 41:1999;276-284.
77. Podo F. Tumour phospholipid metabolism. NMR Biomed. 12:1999;413-439.
78. 2: role in physiologic and inflammatory processes. J. Lipid Mediat. 8:1993;161-167.
79. Richardson A.J., Allen S., Hajnal J.V., Puri B.K. Associations between central and peripheral measures of phospholipid breakdown revealed by cerebral 31-phosphorus MRS and fatty acid composition of erythrocyte membranes. International Society for Magnetic Resonance in Medicine, Eighth Scientific Meeting and Exhibition. Denver CO :2000.
80. 2) activity in gerbil brain: enhanced activities of cytosolic, mitochondrial, and microsomal forms after ischemia and reperfusion. J. Neurosci. 11:1991;1829-1836.
81. 1H MRS study of probable Alzheimer's disease and normal aging: implications for longitudinal monitoring of dementia progression. Magn. Reson. Imaging. 17:1999;291-299.
82. Ross B., Michaelis T. Clinical applications of magnetic resonance spectroscopy. Magn. Reson. Q. 10:1994;191-247.
83. Ross B.D., Danielsen E.R., Bluml S. Proton magnetic resonance spectroscopy: the new gold standard for diagnosis of clinical and subclinical hepatic encephalopathy? Dig. Dis. 14:(Suppl. 1):1996;30-39.
84. 2 activity in human brain. J. Neurochem. 64:1995;2213-2221.
85. 2 activity. J. Neurochem. 70:1998;786-793.
86. 1H magnetic resonance spectroscopy for the discrimination of primary brain tumors. Invest. Radiol. 34:1999;230-235.
87. Sappey-Marinier D., Hubesch B., Matson G.B., Weiner M.W. Decreased phosphorus metabolite concentrations and alkalosis in chronic cerebral infarction. Radiology. 182:1992;29-34.
88. Saunders D.E., Howe F.A., van den Boogaart A., Griffiths J.R., Brown M.M. Aging of the adult brain: in vivo quantitation of metabolite content with proton magnetic resonance spectroscopy. J. Magn. Reson. Imaging. 9:1999;711-716.
89. 2 is activated after experimental closed head injury in the rat. J. Neurochem. 53:1989;1541-1546.
90. Simmons A., Smail M., Moore E., Williams S.C. Serial precision of metabolite peak area ratios and water referenced metabolite peak areas in proton MR spectroscopy of the human brain. Magn. Reson. Imaging. 16:1998;319-330.
91. 1H-MR spectroscopy for metabolic characterisation of diffuse and focal brain lesions in patients infected with HIV. J. Neurol. Neurosurg. Psychiatry. 64:1998;516-523.
92. 2) immunoreactivity is elevated in Alzheimer's disease brain, Neurobiol. Dis. 3:1996;51-63.
93. Stoll A.L., Renshaw P.F., De Micheli E., Wurtman R., Pillay S.S., Cohen B.M. Choline ingestion increases the resonance of choline-containing compounds in human brain: an in vivo proton magnetic resonance study. Biol. Psychiatry. 37:1995;170-174.
94. Tackey R.N., Kassim O.O. Macrophage responses to Toxoplasma antigens in vitro: a possible role in inflammatory lesions in toxoplasmosis. Am. J. Trop. Med. Hyg. 61:1999;272-279.
95. Tan J., Bluml S., Hoang T., Dubowitz D., Mevenkamp G., Ross B. Lack of effect of oral choline supplement on the concentrations of choline metabolites in human brain. Magn. Reson. Med. 39:1998;1005-1010.
96. Taylor-Robinson S.D., Buckley C., Changani K.K., Hodgson H.J., Bell J.D. Cerebral proton and phosphorus-31 magnetic resonance spectroscopy in patients with subclinical hepatic encephalopathy. Liver. 19:1999;389-398.
97. Taylor-Robinson S.D., Sargentoni J., Mallalieu R.J., Bell J.D., Bryant D.J., Coutts G.A., Morgan M.Y. Cerebral phosphorus-31 magnetic resonance spectroscopy in patients with chronic hepatic encephalopathy. Hepatology. 20:1994;1173-1178.
98. Taylor-Robinson S.D., Sargentoni J., Marcus C.D., Morgan M.Y., Bryant D.J. Regional variations in cerebral proton spectroscopy in patients with chronic hepatic encephalopathy. Metab. Brain Dis. 9:1994;347-359.
99. Taylor-Robinson S.D., Turjanski N., Bhattacharya S., Seery J.P., Sargentoni J., Brooks D.J., Bryant D.J., Cox I.J. A proton magnetic resonance spectroscopy study of the striatum and cerebral cortex in Parkinson's disease. Metab. Brain Dis. 14:1999;45-55.
100. Tedeschi G., Lundbom N., Raman R., Bonavita S., Duyn J.H., Alger J.R., Di Chiro G. Increased choline signal coinciding with malignant degeneration of cerebral gliomas: a serial proton magnetic resonance spectroscopy imaging study. J. Neurosurg. 87:1997;516-524.
101. 2 from rat brain. Biochem. J. 306:(Part 1):1995;305-309.
102. Thompson W., Dawson R.M.C. The triphosphoinositide phosphodiesterase of brain tissue. Biochem. J. 91:1964;237-243.
103. 13C nuclear magnetic resonance investigations of choline metabolism in rabbit brain. Magn. Reson. Med. 13:1990;90-102.
104. 1 present in brain and testicular tissue. J. Biochem. (Tokyo). 125:1999;1001-1010.
105. Vion-Dury J., Salvan A.-M., Cozzone P.J. La spectrométrie de résonance magnétique du proton dans l'exploration non invasive du métabolisme cérébral humain: applications cliniques actuelles et futures. Prog. Neurol. 155:1999;903-926.
106. 2 in human melanoma tumor cells. J. Immunol. 156:1996;201-207.
107. 31P magnetic resonance spectroscopy in the frontal lobe of major depressed patients. Eur. Arch. Psychiatry Clin. Neurosci. 248:1998;289-295.
108. 31Phosphorus magnetic resonance spectroscopy of the dorsolateral prefrontal region in schizophrenics - a study including 50 patients and 36 controls. Biol. Psychiatry. 44:1998;399-404.
109. Waite M. The phospholipases. Hanahan D.J. Handbook of Lipid Research. Vol. 5:1987;332 Plenum Press, New York.
110. Winsberg M.E., Sachs N., Tate D.L., Adalsteinsson E., Spielman D., Ketter T.A. Decreased dorsolateral prefrontal N-acetyl aspartate in bipolar disorder. Biol. Psychiatry. 47:2000;475-481.
111. 1H MR spectroscopy in children with Canavan's disease. J. Magn. Reson. Imaging. 6:1996;889-893.
112. 2 in canine myocardium. J. Biol. Chem. 260:1985;7295-7303.
113. Wolinsky J.S., Narayana P.A., Fenstermacher M.J. Proton magnetic resonance spectroscopy in multiple sclerosis. Neurology. 40:1990;1764-1769.
114. Yamagata N.T., Miller B.L., McBride D., Chang L., Chiang F., Nikas D., Osborne D., Buchthal S.D. In vivo proton spectroscopy of intracranial infections and neoplasms. J. Neuroimaging. 4:1994;23-28.